|
News For BMY;PFE From The Last 14 Days Check below for free stories on BMY;PFE the last two weeks. |
|
|
| May 20, 2013 |
| 17:04 EDT |  | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
 Subscribe for More Information |
|
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 06:30 EDT |  | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT |  | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT |  | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 08:55 EDT |  | BMY, PFE | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT | | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
| |
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
|
| May 15, 2013 |
| 11:28 EDT | | BMY | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
|
| 09:43 EDT | | BMY | Active equity option families trading on open
Subscribe for More Information |
|
| May 14, 2013 |
| 07:24 EDT | | BMY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 16:29 EDT |  | PFE | On The Fly: Closing Wrap
Subscribe for More Information |
|
| 12:31 EDT | | PFE | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 11:48 EDT | | BMY, PFE | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 09:21 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:08 EDT | | PFE | Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership
Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. |
|
| 07:46 EDT | | PFE | DURECT says additional clinical studies needed for Remoxy
DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39. |
| |
|
|
|
|
